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Abstract
E3 ubiquitin ligases of which there are >600 putative in humans, constitute 
a family of highly heterogeneous proteins and protein complexes that are the 
ultimate enzymes responsible for the recruitment of an ubiquitin loaded E2 
ubiquitin-conjugating enzyme, recognise the appropriate protein substrate and 
directly or indirectly transfer the ubiquitin load onto the substrate. The aftermath 
of an E3 ligase activity is usually the formation of an isopeptide bond between the 
free carboxylate group of ubiquitin’s C-terminal Gly76 and an ε-amino group of the 
substrate’s Lys, even though non-canonical ubiquitylation on non-amine groups 
of target proteins have been observed. E3 ligases are grouped into four distinct 
families: HECT, RING-finger/U-box, RBR and PHD-finger. E3 ubiquitin ligases 
play critical roles in subcellular signalling cascades in eukaryotes. Dysfunctional E3 
ubiquitin ligases therefore tend to inflict dramatic effects on human health and may 
result in the development of various diseases including Parkinson’s, Amyotrophic 
Lateral Sclerosis, Alzheimer’s, cancer, etc. Being regulators of numerous cellular 
processes, some E3 ubiquitin ligases have become potential targets for therapy. This 
chapter will present a comprehensive review of up-to-date findings in E3 ligases, 
their role in the pathology of disease and therapeutic potential for future drug 
development.
Keywords: classification, disease, E3 ligases, dysfunction, mechanism, therapeutics, 
ubiquitin
1. Introduction
1.1 E3 ubiquitin ligases in Ubiquitylation
E3 ubiquitin ligases play crucial roles in ubiquitin conjugation to substrates and 
therefore ubiquitin signalling. Protein ubiquitylation (also referred to as ubiquitina-
tion) is a dynamic multifaceted post-translational modification in which ubiquitin 
is covalently attached to a specific protein target in a three-step enzymatic cascade 
involving the action of an E1 ubiquitin-activating enzyme, E2 ubiquitin-conju-
gating enzyme and E3 ubiquitin ligase [1]. An E3 ubiquitin ligase is the ultimate 
enzyme which directly or indirectly catalyses the transfer and subsequent ligation 
of an ubiquitin monomer to a specific target protein (i.e., the substrate). The 
aftermath of ubiquitylation is usually the formation of an isopeptide bond catalysed 
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by the E3 ligase between the free carboxylate group of ubiquitin’s C-terminal Gly76 
and an ε-amino group of the substrate’s Lys [2]. However, non-canonical ubiqui-
tylation in which ubiquitin is conjugated to the target protein’s N-terminal amino 
group of Met has been observed in more than 22 proteins including ubiquitin itself 
[3–5]. There is also increasing evidence of ubiquitylation on non-amine groups of 
target proteins including the thiol groups of Cys [6] and the hydroxyl groups of Thr, 
Ser and probably Tyr [7].
In the initial ATP-dependent activation step of ubiquitylation, E1 catalyses 
the acyl-adenylation of ubiquitin’s C-terminus for conjugation by forming an 
ubiquitin-adenylate intermediate (Figure 1). In the second step, ubiquitin is trans-
ferred to the active site Cys residue resulting in the formation of a thioester linkage 
between the C-terminal carboxyl group of ubiquitin and the E1 Cys sulphhydryl 
(-SH) group with a consequential release of AMP [8]. Ubiquitin is then transferred 
from the ubiquitin-adenylate intermediate in the subsequent transthiolation 
reaction to the -SH group of the catalytic Cys of an E2 enzyme [9]. In the final 
ligation step, E3 binds both the target protein and the ubiquitin-charged E2 and 
facilitates the transfer of ubiquitin from E2 to the ε-amino group of a Lys in the 
target protein. E3 enzymes thus function as the substrate recognition modules and 
consequently determine substrate specificity of ubiquitin conjugation, while the 
E2s determine the chain type of polyubiquitylation [10, 11]. Human cells possess 
two E1 enzymes (UBA1, UBA6), approximately 40 E2 enzymes and more than 600 
putative E3 enzymes [12–15]. This notwithstanding, ubiquitin-chain elongation 
factors (E4 enzymes e.g., the mouse double minute 2 homologue (mdm2)) which 
extend pre-existing polyubiquitin chains on substrate proteins (e.g., the tumour 
suppressor p53) have also been reported [16, 17].
Figure 1. 
The ubiquitin-mediated proteasome proteolytic pathway. Ubiquitin modification is an ATP-dependent process 
carried out by three classes of enzymes, E1, E2 and E3 which specifically target proteins to either change their 
activity or their location, or in some cases earmark target proteins for proteasome-mediated degradation. E1 
forms a thioester bond with ubiquitin which allows subsequent transfer of ubiquitin to E2, followed by the E3 
ligation of an isopeptide bond between the carboxyl-terminus of ubiquitin and a Lys residue on the substrate 
protein. Isopeptide bonds between ubiquitin and ubiquitin or ubiquitin and other target proteins can, however, 
be hydrolysed by deubiquitylating enzymes (DUBs).
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1.2 Cellular functions of ubiquitylation in eukaryotes
Ubiquitin’s versatility in the regulation of cellular processes is by virtue of its 
ability to covalently modify other proteins [18]. Post-translational modifications, 
which are usually covalent and reversible, may alter the properties and therefore, 
the functions of the modified protein. A major function of ubiquitin is regulation of 
the degradation of other specific proteins, literally referred to as ‘the molecular kiss 
of death’ [19–21]. The 26S proteasome is responsible for degradation and recycling 
of unwanted, short-lived, inactive, oxidised, unfolded and/ or misfolded proteins 
(Figure 1) [22, 23]. Proteasomal proteolysis enables the cell to rid itself of these 
misfolded or damaged proteins and re-adjusts the concentration of essential pro-
teins so that cellular homeostasis is maintained [24]. For a condemned protein to be 
recognised by the 26S proteasome, a polyubiquitin chain of at least four ubiquitin 
molecules must be covalently attached to a substrate Lys residue [25]. The protea-
some is a barrel-shaped multisubunit protein complex, consisting of two chambers 
within which proteolysis occurs. The eukaryotic 20S proteasome is the catalytic 
portion of the 26S proteasome. The 19S regulatory complex mediates substrate 
recognition and substrate unfolding (Figure 1). Exploration of the ubiquitin system 
in eukaryotes has shown that the chemical modification of proteins by ubiquitin 
is an incredibly important post-translational event that is crucial to numerous 
complicated cellular processes beyond the ubiquitin proteasome system. Ubiquitin 
conjugation also plays a wide variety of roles that are independent of proteasomal 
degradation [2, 18]. The ubiquitin code modulates cell cycle progression, dif-
ferentiation, signal transduction, protein–protein interactions, and intracellular 
protein trafficking. Ubiquitin regulates subcellular localisation of proteins where 
they control other protein function and cell mechanisms. Transcription, autophagy, 
inflammatory signalling, modulation of enzymatic activity, DNA repair, heat shock 
responses, chromatin structure, embryogenesis, cell apoptosis, virus budding, 
vacuolar protein sorting, inflammatory response and receptor endocytosis are also 
regulated by ubiquitin-mediated signalling [26, 27]. The cellular environment must 
constantly maintain homeostatic conditions. The ubiquitin-proteasome system 
is the major ubiquitin-mediated process recognised as the cellular quality control 
system [28]. Deubiquitylating enzymes (DUBs) cleave isopeptide bonds releasing 
free ubiquitin residues from protein substrates. As such DUBs are also implicated 
in the regulation of cellular events by trimming (poly)ubiquitin conjugates and 
recycling ubiquitin monomers.
1.2.1 Ubiquitin modifications
The functional consequences of ubiquitylation vary because of recognition by 
different ubiquitin-binding modules which can distinguish different polyubiquitin 
modifications. Monoubiquitylation is the conjugation of a single ubiquitin molecule 
to a single Lys of the target protein. Multimonoubiquitylation occurs when a target 
protein is tagged with more than one single molecule of ubiquitin. In polyubiq-
uitylation, the target protein is tagged with an ubiquitin chain linked through the 
C-terminal Gly of each ubiquitin unit and a specific internal Lys of the previously 
attached ubiquitin through sequential rounds of ubiquitylation (Figure 1). The 
presence of N-terminal Met including seven Lys residues per ubiquitin moiety on 
which polyubiquitylation occurs, empowers ubiquitin with potential to exhibit 
diverse and highly complicated linkage specific post-translational modification of 
target proteins [29]. Unlike homogenous chains of ubiquitin which contain a single 
ubiquitin-ubiquitin linkage type, heterogeneous polyubiquitin chains contain more 
than one linkage type. In mixed polyubiquitin chains therefore, one linkage type 
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can be extended by a second type, forming a non-branched structure. In branched 
polyubiquitin chains however, different linkage types form one or more branches 
(i.e., multiple Lys residues in the same ubiquitin) [29].
Monoubiquitylation has been implicated in the endocytic trafficking of 
certain cargo proteins, e.g., small GTPases and receptors (e.g., Epidermal Growth 
Factor Receptor, EGFR) to specific cellular compartments at different stages of 
the endocytic pathway. Monoubiquitylation has also been implicated in gene 
expression and DNA repair [30–33]. Multimonoubiquitylation is important for 
receptor endocytosis [34]. Lys48-linked polyubiquitylation (i.e., polyubiquitin 
chains linked via Lys48 of the proximal ubiquitin to the next ubiquitin moiety in 
the chain) has predominantly been linked to targeting proteins for proteasomal 
degradation [35]. Lys63-linked polyubiquitin chains function as scaffolds to 
assemble signalling complexes e.g., activation of transcription factor NF-κB 
involved in inflammatory and immune response, DNA damage tolerance, the 
endocytic pathway and ribosomal protein synthesis [36]. It has been demon-
strated that unanchored (substrate-free) Lys63-linked polyubiquitin chain 
assembled via UBE2N/UBE2V1 (E2) and TRAF6 (E3) enzymes activate the NF-κB 
pathway by activation of TAK1 which in turn phosphorylates and activates IκB 
kinase (IKK) [37]. Linear linkage via N-terminal Met is also reported to regulate 
NF-κB signalling [38–40].
2. Types of E3 ubiquitin ligases
Based on considerations of structure, chemistry, and mechanisms by which 
ubiquitin is transferred to the substrate, four families of E3 ubiquitin ligases are 
distinguishable. These include homologous to the E6AP carboxyl terminus (HECT), 
Really Interesting New Gene (RING)-finger/U-box, RING-between RING (RBR) 
and the recently characterised plant homeodomain (PHD)-finger ligases.
2.1 RING-finger E3 ligases
The RING E3s constitute the largest family of E3 ligases. RING-finger E3 fam-
ily of ligases include the U-box ligases. Although able to promote the formation of 
polyubiquitin chains, RING-Finger/U-box E3s lack a catalytic site and hence, do 
not participate directly in catalysis. RING-type E3s are characterised by the pres-
ence of the canonical Cys3HisCys4 amino acid motif (i.e., the RING domain) and 
consequently mediate the direct transfer of ubiquitin from E2 ~ ubiquitin complex 
to the substrate (Figure 2a). Each canonical Zn finger (Cys3HisCys4) type domain 
binds two Zn2+ ions which are critical to its stability. RING E3 ligases can exist and 
act as single-subunits e.g., CHIP/Stub1, mdm2, RNF4, RNF114, UBE4B (Figure 2a) 
or may be assembled on a Cullin scaffold to form multiple subunits. Multi-subunit 
RING E3s contain a substrate receptor (responsible for substrate specificity) at the 
C-terminus, an adaptor(s), a Cullin- and a RING-box at the N-terminus (Figure 2b). 
The APC (anaphase-promoting complex) and the SCF (Skp1-Cullin-F-box protein) 
complex are examples of multi-subunit RING E3s involved in substrate recognition 
and are the most abundant type of RING E3s [41, 42]. RING-finger E3 ubiquitin 
ligases regulate several cellular processes, including cell metabolism, cell prolifera-
tion, apoptosis, differentiation, and DNA repair making them potential targets 
for anti-cancer drug development. There is evidence to suggest that RING-finger 
domains can also allosterically activate the E2 enzymes [43]. RING E3 ligase activity 
is often regulated by neddylation, phosphorylation and protein–protein interactions 
with small molecules among others.
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2.1.1 U-box E3 ligases
The U-box proteins contain a U-box domain of ~70 amino acids which lacks the 
characteristic Zn chelating Cys and His residues in RING-finger domain and are 
characteristically stabilised by a network of H-bonds within each loop, flanked by a 
central α-helix [44–46]. U-box E3s are more abundant in plants than animals [47]. 
Both RING and U-box domains are responsible for binding the ubiquitin-charged 
E2 and stimulating the transfer of ubiquitin to substrate (Figure 2). Additionally, 
RING and U-box E3 ligases can function as monomers (Figure 2a), homodimers 
(Figure 2c and d), or heterodimers. In a homodimer, each monomer can bind an 
E2, but apparently not the case in the heterodimeric RINGs.
2.2 PHD-finger E3 ligases
Another RING-related family of E3s are the PHD E3 ligases. Unique sequence 
and structural signatures that distinguish the PHD-finger from RING fingers have 
been demonstrated indicating that the PHD-fingers function primarily as E3 ligases 
Figure 2. 
Illustration of RING/U-box E3 ligase types and their mechanism of ubiquitin transfer to target proteins.
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that promote protein degradation and constitute a distinct class of E3 ligases. The 
PHD or leukaemia-associated-protein (LAP) domain resembles the RING finger 
domain [48–50]. It also has the eight conserved metal binding ligands, Cys4HisCys3 
consensus, with similar spacing [51] however, it represents a variant of the RING 
finger. An example of a PHD domain E3 ligase is Mekk1 kinase. The second 
N-terminal Cys-rich domain of Mekk1 kinase has been shown to exhibit E3 ubiq-
uitin ligase activity toward ERK1/2 and is involved in the down regulation of the 
MAP kinase cascade [52]. The PHD domain is found in many proteins involved in 
chromatin-mediated transcriptional regulation [53], however, very little is known 
about their precise functions.
2.3 HECT E3 ligases
Unlike the RING-finger E3s, the HECT type E3s instead contain a conserved 
C-terminus HECT domain which consists of a larger N-terminal bi-lobe architec-
ture encompassing the E2-binding site and a smaller C-terminal lobe which com-
prises the active-site Cys residue (Figure 3a). Their reaction cycle consists of three 
steps; binding to an E2 ~ ubiquitin, transiently loading ubiquitin on themselves via 
formation of a covalent ubiquitin-thioester linked intermediate with the catalytic 
Cys, before transferring the ubiquitin molecule onto the target protein [54]. These 
two lobes are connected by a flexible hinge region, which is critical for juxtaposing 
the catalytic Cys residues of the E2 and E3 during ubiquitin transfer (Figure 3a). 
A conformational change involving an alteration in the relative orientation of the 
two lobes is thought to facilitate the transthiolation reaction [54–56]. Whereas the 
C-terminal HECT domain is responsible for E3 catalytic activity, the N-terminal 
portion is highly variable and determines the substrate specificity. HECT domain 
containing E3 ligases are estimated at 30 in mammals and 28 in humans out of the 
over 600 E3s [57]. Human HECT E3s can further be categorised into subfamilies 
based on the mode of protein–protein interactions of their N-terminal domain 
extensions which determine their substrate specificity. These include the Nedd4 
family, which are characterised by the presence of tryptophan-tryptophan (WW) 
motifs, the HERC (HECT and RCC1-like domain) family, which contain one or 
more regulators of chromosome condensation 1 (RCC1)-like domains (RLDs), and 
Figure 3. 
Mechanism of ubiquitin transfer to target protein by (a) HECT and (b) RBR E3 ubiquitin ligases.
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the SI (ngle)-HECT/“other” HECT E3s lacking either WW or RLDs domains but 
contain various other domains. These subfamilies have been extensively reviewed 
[58]. HECT domain E3s play several roles. They determine the specificity of ubiq-
uitylation and mediate the trafficking of many receptors. They are also regulators 
of immune response and several signalling pathways in cell proliferation [59]. 
Naturally, the intrinsic catalytic activity of HECT E3s is normally folded together in 
an autoinhibited state by intramolecular interactions between domains which can 
be released to an active form of the enzyme in response to various signals by unfold-
ing to expose the catalytic Cys.
2.4 RBR E3 ligases
RBR E3 ligases employ the characteristic RING-HECT hybrid mechanism 
[60–65]. Like the HECT E3 ligases, the RBR E3 ligases catalyse the transfer of 
ubiquitin from E2 to the substrate through a three-step reaction where the RBR E3 
first binds the E2, transfers the ubiquitin load to its catalytic Cys and subsequently 
to the substrate (Figure 3b). RBR E3 ubiquitin ligases differ from RING-type E3 
mainly because they possess an active site which is absent in other RING-type 
E3s. However, like RING E3s, the RBR E3 ligases have four RING Zn2+ finger 
domains. Each of these domains coordinates two Zn2+ ions through His and Cys 
residues. They include the canonical Cys3HisCys4-type RING (named RING1) 
domain as in RING E3s, that binds the E2 enzyme followed by; in-between-RING 
(IBR) domain and RING2 domain which contains the active site Cys residue (Figure 
3b). The name RBR was derived from the presence of two predictable RING1 and 
RING2, separated by an IBR (i.e., the RING1-IBR-RING2 module). Though RING2 
domain possesses the catalytic Cys (Figure 3b), it does not conform to the canonical 
RING E3 structure, and it has also been called Rcat (required-for-catalysis) domain. 
The IBR domain is conserved among RBR E3 family of ligases. Its specific function 
remains elusive. The IBR domain adopts the same structural fold as RING2 domain, 
however, it lacks the essential catalytic Cys residue and is sometimes referred to 
as the BRcat (benign-catalytic) domain [66]. The Zn2+ ions bound within RING 
domains are also reported to be essential for structural stability and proper regula-
tion of its intrinsic enzymatic activity. Their removal from parkin for instance, 
result in near complete unfolding of the protein [67, 68]. HHARI and Parkin were 
initially characterised to have the hybrid mechanism [64]. TRIAD1, RNF144A, 
HOIP, and HOIL-1 L have later been characterised to employ the same RING-HECT 
hybrid mechanism [69]. RBR RING domains are also normally involved in intramo-
lecular interactions between amino acids of different domains that keep the enzyme 
in a coiled autoinhibited state. Through different molecular mechanisms such as 
phosphorylation and protein–protein interactions, the uncoiling of closed-compact 
or folded autoinhibited states of RBR E3 ligases may be triggered thereby exposing 
the catalytic sites and increasing the intrinsic E3 ligase activity.
3. Implication of the E3 ubiquitin ligases in disease and therapy
3.1 Role of E3 ligases in disease
Aberrations of ubiquitin signalling are often associated with pathogenesis of 
several diseases and genetic disorders [58, 70–73]. Errors in ubiquitin signalling 
processes result in defective autophagy and mitophagy, DNA repair mecha-
nisms, NF-kB signalling, etc. [74]. Subsequently, associated diseases including 
Parkinson’s, Amyotrophic Lateral Sclerosis, Alzheimer’s, cancer, systemic lupus 
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erythematosus, rheumatoid arthritis, and inflammatory bowel diseases (e.g., 
Crohn’s disease and ulcerative colitis) among several others may ensue [75, 76]. 
Ubiquitin E3 ligases, most notably RING finger and RING finger-related E3s are 
fundamental to the specificity of the ubiquitin proteasome system. Many RING 
finger E3s are implicated in either the suppression or the progression of cancer 
and cancer chemoresistance [58, 75, 77, 78]. Due to limited space only some key 
E3-linked diseases have been explained below.
Parkin, a RBR E3 ligase functions in the covalent attachment of ubiquitin to 
specific substrates e.g., outer mitochondrial membrane proteins – Mfn1, Mfn2, 
and Miro GTPases [62]. Parkin is involved in protein degradation, collaborating 
with the ubiquitin-conjugating enzyme, UbcH7 [79, 80]. Even though much of 
the aetiology of Parkinson’s disease remains largely unknown, malfunctioning of 
PINK1 and/or parkin causes accumulation of damaged mitochondria, which trigger 
familial parkinsonism. Parkinson’s disease (named after Dr. James Parkinson, 
AD1783–1824) is a neurodegenerative movement disorder caused by the progressive 
death of dopamine producing neurons in the substantia nigra pars compacta of the 
mid-brain [81]. The characteristic symptoms of Parkinson’s disease include muscle 
tremor, muscle rigidity, slowness of movement (bradykinesia) and postural insta-
bility [82–85]. Parkinson’s disease is the second most common neurodegenerative 
disease after Alzheimer’s, affecting predominantly, individuals above 65 years even 
though earlier onset have been reported [79, 84, 86, 87]. Early-onset Parkinson’s 
disease (EOPD - onset in individuals before 50 years) which account for approxi-
mately 5–10% of all cases of Parkinson’s disease are attributable to monogenic 
causes [88, 89]. Mutations in coding regions of PARK2 gene are often implicated 
as the most common cause of autosomal-recessive juvenile Parkinsonism (AR-JP) 
(EOPD), followed by PINK1 gene variants resulting in a loss of kinase function 
which apparently, is required for parkin phosphorylation and subsequent activa-
tion [84, 90–93]. This renders PINK1 and parkin proteins vital targets for drug 
development. Greater than 120 pathogenic Parkinson’s disease mutations are spread 
throughout parkin’s four domains, indicating the critical functions for each of the 
individual domains [94].
The multi-functional pathways regulated by RING-type E3 ubiquitin ligases 
in inflammatory signalling and consequential inflammatory bowel disease have 
been expansively reviewed by several researchers [73]. Inflammatory bowel dis-
ease is characterised by inflammation of the digestive tract and patients present 
with anomalies in gut microbiota composition e.g., increased levels of harmful 
bacterial strains, reduced levels of bacterial diversity and protective probiotics. 
These trigger proinflammatory intestinal pathogenic immune responses which in 
turn induce intestinal mucosal inflammation. Examples of implicated RING E3 
ligases in inflammatory bowel diseases include, TRAF5, TRAF3, TRAF2, UHRF1, 
RNF183, RNF40, RNF20, RNF170, and RNF186 [73]. For instance, RNF170 E3 
ligase ubiquitylates TLR3 for proteasomal degradation. TLR3 is a pattern recogni-
tion receptor which recognises pathogen-associated molecular patterns (PAMPs) 
of lipopolysaccharides, flagellin, and microbial nucleic acids and triggers activation 
of downstream effectors in innate immune responses. Proteasomal degradation of 
TL3 therefore suppresses TLR3-mediated innate immunity in macrophages thereby 
promoting inflammatory diseases [95]. Several sites of the NF-kB pathway are 
regulated by ubiquitylation. NF-kB constitutes a family of conserved transcription 
factors well known to regulate several cell processes particularly inflammatory 
responses, cell proliferation and apoptosis. NF-kB signalling is therefore associ-
ated with several diseases such as asthma, arthritis, cancer, etc. [96]. For instance, 
RNF183 upregulates proinflammatory responses via NF-κB signalling by ubiqui-
tylating IκBα- the inhibitor of c-Rel/p50 heterodimer, for proteasomal degradation 
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which may induce intestinal mucosal inflammation [97]. Receptors that stimulate 
the NF-kB pathway following various stimuli include CD30, CD40, RABK, TNF-α, 
TCR, and TLRs. In contrast, TRAF2 and TRAF3 catalyse Lys48-linked ubiquity-
lation of c-Rel and interferon regulatory factor 5 thereby signalling their degrada-
tion by the proteasome. This in turn inhibits biosynthesis of proinflammatory 
cytokines, thereby down regulating immune responses in macrophages [98, 99].
The roles of E3 ubiquitin ligases in the RTK pathway (e.g. EGFR) and MAPK 
pathway and other oncogenic/tumour suppressive signalling pathways in glioblas-
toma have been expounded including validation of the potential of E3 ligases as 
future therapeutic interventions for glioblastoma treatment [72]. Glioblastoma is 
a malignant brain tumour which is characterised by a mutation in the metabolic 
enzyme isocitrate dehydrogenase 1 with limited treatment options [100]. In glio-
blastoma, 67% of cases have mutation in at least 1 RTK and about 20% of classical 
tumours express a truncated form of EGFR (EGFRvIII). RTK signalling is down 
regulated by several E3 ligases such as Cbl, Chip and parkin [72]. Ubiquitylation of 
EGFR by Cbl E3 ligase results in clathrin-mediated internalisation of the receptor 
and subsequent sorting into lysosomes where the receptor is degraded and there-
fore reduces EGFR signalling in glioblastoma. LZTR1 is the substrate recognition 
domain of a Cul3 E3 ubiquitin ligase complex. Mutations in LZTR1 are associated 
with schwannomatosis and Noonan syndrome in which loss of LZTR1 function 
drives de-differentiation and proliferation of cells. LZTR1 is also mutated or deleted 
in about 4% or 20% of glioblastoma cases respectively, where mutations of LZTR1 
increase Ras-dependent proliferation of cells coupled with increased resistance 
to tyrosine kinase inhibitors (glioblastoma chemotherapy) because of enhanced 
MAPK signalling [101, 102]. The MAPK pathway is a commonly mutated pathway 
in human cancers. It upregulates cellular phenotypes such as proliferation, differen-
tiation, migration, and invasion.
The BRCA1 RING-type E3 ubiquitin ligase is a human tumour suppressor gene 
and plays critical roles in DNA repair. Mutation of BRCA1 is associated with the 
inherited predisposition for breast and ovarian cancers [102]. The E3/E4 ubiquitin 
ligase, mdm2 is an important negative regulator of the p53 tumour suppressor gene 
as mentioned earlier. p53 protein regulates the cell cycle, DNA repair and induces 
cell apoptosis, hence it functions as a tumour suppressor. Mdm2 serves as an E3 
ubiquitin ligase of p53. This implies that increased activity of the mdm2 oncogenic 
protein via augmented mdm2 expression induces tumorigenicity especially those 
50% that retain wild-type p53. In addition, inactive mdm2 results in increased 
cellular levels of p53, which is detrimental to cells and may accelerate the ageing 
process by excessive apoptosis [103]. It has also been reported that SIAH2 is a RING-
finger E3 ligase which contributes to the progression of various malignant tumours, 
including breast carcinoma, lung and prostate tumours, and oral cancer [104–106]. 
Furthermore, the E3 ligase, c-Cbl has also been demonstrated to be frequently 
dysregulated in myelodysplastic myeloproliferative neoplasms and additionally 
associated with myelodysplastic syndromes, myeloid neoplasms, and primary 
colorectal cancer [75].
Multiple studies have implicated several E3 ubiquitin ligases in ovarian cancer 
chemoresistance which hamper improvement of ovarian cancer patient outcome 
through degradation of various chemoresistance-related substrates in ovarian 
cancer. Among several studies, [107] demonstrated that NEDD4-2 protein (an E3 
ligase that regulates endocytosis and lysosomal degradation of ENaC and other 
channels) expression is reduced in invasive ovarian epithelial cancer tissues com-
pared with non-cancer ovarian tissue suggesting an important role of NEDD4-2 in 
the regulation of chemoresistant ovarian cancer [58]. Indeed Nedd4-1 and Nedd4-2 
E3 ligases have been demonstrated to mediate numerous pathophysiological 
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processes [108]. Briefly, Nedd4-1 mediates endosomal trafficking of receptor 
tyrosine kinases, such as EGFR and fibroblast growth factor receptor (FGFR), by 
ubiquitylating endocytic or vesicle sorting proteins. Nedd4-1 is overexpressed in 
lung epithelial cells and is associated with lung cancer progression [109]. NEDD4-1 
can promote Alzheimer’s disease by weaking synaptic strength through ubiquity-
lation of AMPAR (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor) and cytoplasmic internalisation. Nedd4-2 knockout mice reportedly die 
perinatally due to failure of the pups to breathe resulting from increased ENaC 
expression, extensive fibrosis, and infiltration of inflammatory cells in the alveolar 
spaces [110]. This indicates the important regulatory functions of Nedd4-2 in the 
respiratory system. Ubiquitylation of ENaC by Nedd4-2 E3 ligase through direct 
binding to its conserved proline-rich PY motif in the C-terminals results in sodium 
current decrease and associated lung oedema [111]. UBR5/EDD is an E3 ligase that 
mediates the accumulation of ubiquitylated-H2A and -H2AX at DNA damage sites, 
and G2 checkpoint control. UBR5 is reported to enhance cell survival and cisplatin 
resistance by regulation of expression of the pro-survival protein myeloid cell 
leukaemia sequence 1 (Mcl-1) and is an undesirable prognostic factor for patients 
with serous epithelial ovarian cancer [112]. UBR5 influences ovarian cancer cell 
cisplatin resistance by mediating MOAP-1 ubiquitylation and degradation through 
cooperation with Dyrk2 kinase [113].
BCL6 proto-oncogene is the transcription factor implicated in the pathogenesis 
of human B-cell chronic lymphocytic leukaemia. Deregulation of BCL6 expression 
or increased degradation are pathogenic events in many lymphomas. Mutation 
of the multi-subunit SCF FBXO11 E3 ligase is associated with the development of 
B-cell lymphomas. FBXO11 is the substrate recognition component of the ligase 
and functions as a tumour suppressor by targeting BCL6 transcription factor for 
proteasomal degradation [114, 115]. BCL6 binds to specific DNA sequences and 
down regulates transcription of a variety of genes involved in B-cell development, 
differentiation and activation including the transcription of STAT-dependent IL-4 
responses of B-cells [116].
FANCL is a multisubunit E3 ubiquitin-protein ligase that monoubiquitylates 
FANCD2 and FANCI, a key step in the DNA damage repair pathway. FANCL 
contains a RING finger-like PHD domain with E3 activity [78, 117]. Mutations 
in 8 out of 13 components of the FANCL complex cause Fanconi anaemia (FA). 
Individuals with this condition experience severe multiple congenital and haema-
tological abnormalities including predisposition to development of a variety of 
cancers [118]. Individuals may experience congenital skeletal anomalies especially 
of thumb and forearm. They also display endocrine abnormalities, short stature 
correlating to growth hormone production and hyperthyroidism among several 
other anomalies [119].
Mutations in von Hippel–Lindau (VHL), the substrate recognition component 
of Cullin RING E3 ubiquitin ligase (CRL2VHL), results in an autosomal-dominant 
familial VHL syndrome. This implies that a mutation in just one copy of the VHL 
gene in each cell is enough to increase risk of developing VHL disease. Substrates 
for CRL2VHL E3 ligase tumour suppressor include the hypoxia-inducible factor 
(HIF) family of transcription factors (HIF1-3α) which bind the VHL subunit when 
hydroxylated on two proline residues by prolyl hydroxylase. This results in ubiqui-
tylation of HIF1-3α and subsequent proteasomal degradation which would other-
wise accumulate and cause inappropriate upregulation of hypoxia-inducible genes 
such as Transforming growth factor alpha (TGF-α), Vascular endothelial growth 
factor A (VEGF-A), etc. leading to hyperangiogenesis in VHL mutant individuals 
[120]. VHL disease is characterised by benign and malignant tumours mostly clear 
cell kidney and lung carcinomas [121]. Hemangioblastomas that develop in the 
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brain and spinal cord cause headaches, vomiting, weakness, and a loss of muscle 
coordination (ataxia). If left untreated, hemangioblastomas may result in blind-
ness, permanent brain damage or death. Pheochromocytomas develop and affect 
the adrenal glands, which may produce excess hormones thereby causing high blood 
pressure.
Angelman syndrome is a complex genetic disorder caused by a disruption of the 
UBE3A gene, which encodes the wild-type ubiquitin ligase E6 associated protein 
(E6-AP/UBE3) [122]. The disease occurs in individuals with a loss of expression or 
mutations in E6-AP. Angelman syndrome is characterised by intellectual disability, 
severe speech impairment, a tendency to jerky movement (ataxia), recurrent 
seizures (epilepsy) and a small head size [123, 124]. Even though investigations have 
established that E6-AP plays an essential role in the proteasome-dependent deg-
radation of several identified cellular substrates and therefore promote Angelman 
syndrome, to date, the molecular mechanisms behind the disease pathology is 
poorly understood [125]. Identified E6-AP substrates include Sox9, C/EBPα, 
α-synuclein, p27, promyelocytic leukaemia (PML) tumour suppressor, annexin A1, 
amplified in breast cancer 1 (AIB1), hHR23A, etc. [126]. This indicates that a func-
tionally defective E6-AP mutant cannot initiate degradation of substrates thereby 
promoting development of Angelman syndrome.
3-M syndrome is a rare autosomal-recessive growth retardation disorder associ-
ated with mutations of the Cullin7 (Cul7) E3 ligase [127]. 3-M syndrome is charac-
terised by severe pre- and postnatal growth retardation, large head circumference, 
facial dysmorphia and skeletal abnormalities including dwarfism even though 
affected individuals exhibit normal intelligence [128]. Cul7 is a member of the 
Cullin family of proteins, which function as scaffolds in the formation of numerous 
E3 ligases with RING proteins, adaptor proteins and substrate recognition recep-
tors [129]. The specific role and substrates of Cul7 are mostly unknown. Recently 
however, evidence of CUL7’s involvement in pivotal growth-regulatory signalling 
have begun to emerge. Cul7 interacts with both Skp1-Fbx29 heterodimer and the 
ROC1 RING-finger protein to form the Cul7 E3 ligase complex which ubiquitylates 
proteins for proteasomal and lysosomal degradation [130]. The insulin receptor 
substrate 1 (IRS-1), a critical mediator of the insulin/insulin-like growth factor 
1 signalling has been identified as a proteolytic target of the Cul7 E3 ligase [131]. 
Additionally, mammalian Eag1 potassium (Eag1 K+) channels, which are widely 
expressed in the brain, are novel targets of Cul7 E3 ligase [130]. Mutant Eag1 K+ 
channels are associated with congenital neurodevelopmental anomalies. Cul7 E3 
ligase has also been implicated in the proteasomal degradation of cyclin D1 [132]. 
Cyclin D1 proto-oncogene is a vital regulator of cell cycle progression from G1 to 
S phase in several different cell types. Accumulation of cyclin D is associated with 
development and progression of cancer and deregulation of its expression is linked 
to resistance to hormone therapy in breast cancer [133]. Consequently, in many 
cancers, impaired activity of Cul7 is essentially responsible for cellular elevated 
levels of cyclin D1.
Ubiquilin (UBQLN), a ubiquitin binding protein, is a ubiquitin-like protein that 
shares a high degree of sequence similarity with ubiquitin across several species. 
UBQLNs contain both N-terminal ubiquitin-like and C-terminal UBA (ubiquitin 
associated) domains and are capable of functionally recruiting E3s and linking 
to the ubiquitylation machinery to proteasomal degradation of targeted proteins 
[134, 135]. Mutations in UBQLNs may be associated with lesions in Alzheimer’s 
and Parkinson’s disease. UBQLNs have also been shown to modulate accumulation 
of presenilin proteins, which play an important role in the generation of ß amyloid 
precursor protein (APP). Presenilin is the sub-component of gamma secretase 
whose role is endoproteolysis of APP [136]. UBQLN-1 is also a molecular chaperone 
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for APP. Therefore, its presence prevents aggregation of APP [137]. Consequently, 
low levels of UBQLN-1 increase malformation of APP thereby triggering 
Alzheimer’s disease [138].
The list of diseases associated with E3 ligase dysfunction is not exhaustive. More 
insights are available in the literature of which each apparently addresses a speci-
fied disease in more detail. It is anticipated that new discoveries in this regard will 
emerge in the future.
3.2 Potential therapeutic benefits of E3 ligases
There remains a significant unmet need for novel therapeutic strategies for 
genetic disorders such as Alzheimer’s, Amyotrophic Lateral Sclerosis, Arthritis, 
cancer, etc. Owing to the critical cellular signalling role of the ubiquitin system in 
protein degradation, activation, subcellular localization and beyond, various targets 
of the ubiquitylation pathway are being earmarked to have potential for develop-
ment of drugs to treat malignant cancers among several other diseases. Among 
these targets include the E3 ubiquitin ligases [41]. So far, some E3 ligase inhibitors 
including Velcade (bortezomib), Ninlaro (ixazomib), and Kyprolis (carfilzomib) 
have proved effective and have been approved by the US FDA for the treatment 
of multiple myeloma suggesting that specific E3 inhibitors are promising in anti-
cancer therapy and beyond. This breakthrough has inspired researchers to probe 
more aspects of the ubiquitylation system for therapeutics [139]. Ideally, a potential 
cancer treatment target should be playing an essential role in carcinogenesis, it 
should overexpress in cancer cells and its activity inhibition or expression should 
induce growth suppression and/or apoptosis in cancer cells [140]. In addition, an 
ideal druggable candidate should be an enzyme or a G Protein Coupled Receptor 
(GPCR) and therefore druggable. More importantly, it is either not expressed or 
is only expressed at low levels in normal cells and its inhibition has minimal effect 
on normal cell growth and function. Inhibition of such a target would achieve a 
maximal therapeutic index with minimal toxicity [140]. Being enzymes and mostly 
natural tumour suppressors, many E3 ligases function within these criteria and are 
therefore attractive targets for therapeutic intervention of cancers. Several studies 
have explored and validated the therapeutic potential of E3 ligases [58, 71, 72]. In 
this section, the rationale for selected E3 ligases with pharmacological potential 
have been reviewed.
Firstly, one therapeutically significant pathway is the PINK1-parkin cascade for 
mitochondrial quality control. PINK1 and parkin appear to offer multiple therapeu-
tic targets for the treatment of Parkinson’s disease and several other neurodegenera-
tive disorders [141, 142]. Unidentified and putative members of this cascade may 
also be therapeutically relevant. Parkin displays low basal activity under normal 
physiological conditions [82]. Any means by which wild-type parkin activity may 
be increased for instance by development of small molecule activators could be 
significant in promoting mitophagy to downregulate progression of Parkinson’s 
disease and other PINK1-parkin pathway-mediated neurodegenerative diseases. In 
PINK1 mutant patients, PINK1 by-pass biomolecules that either mimic phospho-
Ser65-ubiquitin or can disrupt the serpentine autoinhibited tertiary structure of 
parkin could augment its E3 ligase activity and hence, its neuroprotective functions 
[143]. Investigations revealed that primary neuron cells and post-mortem brain 
tissue from Parkinson’s disease patients carrying pathogenic mutant PINK1 were 
largely devoid of phospho-Ser65-ubiquitin signal because phosphorylation of 
ubiquitin at Ser65 is dependent on PINK1 kinase activity [144]. Their data further 
indicated that phospho-Ser65-ubiquitin accumulates with stress, disease or age in 
individuals bearing functional PINK1 and therefore highlight the significance of 
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phospho-Ser65-ubiquitin as a potential candidate for the development of biomarkers 
and therapeutics. In vitro mutagenic investigations have shown that mitochondrial 
depolarisation and PINK1-dependent recruitment of parkin to mitochondria is sig-
nificantly enhanced by mutations at Trp403 in repressor element (REP) or Phe463 
in RING2 of parkin [145]. This knowledge is pharmacologically relevant. The REP 
linker of parkin is anchored through Trp403 with RING1 and prevents E2 binding to 
its site on RING1. REP must dissociate from RING1 to enhance E2 binding. In addi-
tion, RING0 must dissociate from RING2 to expose the active site Cys431 [62, 146]. 
Therefore, any biomolecule capable of binding tightly to the pockets occupied by the 
amino acid side chains can disrupt parkin’s autoinhibited structural state and induce 
UbcH7 binding and discharging thereby enhancing E3 ligase activity. Scientists have 
also shown that the DUBs, USP30 and USP15 function antagonistically to the PINK1-
parkin dependent mitophagy making inhibitors of these enzymes prime candidates 
for designing drugs that will enhance PINK1-parkin dependent mitophagy [147, 
148]. In contrast, USP8 promotes parkin-mediated mitophagy and thus agonists of 
this DUB will enhance mitophagy and neuroprotection [149]. Mutations of PINK1’s 
kinase domain are also observed with Parkinson’s disease patients where parkin 
translocation to mitochondria or mitochondrial aggregation does not occur [95].
As previously mentioned in Section 3.1, mdm2 is a direct downstream target of 
p53. P53, is a well-studied tumour suppressor which is often mutated in more than 
50% of human cancers. This is because p53 induces growth arrest and apoptosis 
upon activation by different stimuli e.g., DNA damage [150]. Upon induction by 
p53, mdm2 in turn acts as an E3 ubiquitin ligase to ubiquitylate p53 for proteasomal 
degradation. This action reduces p53 levels and consequently inhibits p53-mediated 
cell apoptosis [151]. As such, inhibition of mdm2 E3 ligase activity is a potential 
approach to increasing p53 levels in order to induce cell apoptosis in human cancer 
cells harbouring wild-type p53. Mdm2 is usually expressed in low levels in normal 
cells but is overexpressed in several human cancers such as breast carcinomas, soft 
tissue sarcomas, oesophageal carcinomas, lung carcinomas, glioblastomas and 
malignant melanomas and will represent an excellent pharmacological candidate 
for further research [152].
Pirh2 has recently been found to be a major E3 ligase partnering mdm2 to target 
(tetrameric)p53 for proteasomal degradation. Further, the p53-Pirh2 complex 
promotes Twist1 degradation leading to inhibition of epithelial-mesenchymal 
transition in ovarian cancer [153]. Epithelial-mesenchymal transition is critical 
in cancer metastasis and chemoresistance implying that Pirh2 specific inhibition 
might be therapeutically relevant. Some IAPs (Inhibitor of Apoptosis Proteins) 
that are overexpressed in most common human cancers (correlating chemoresis-
tance) also represent important therapeutic targets for drug development [154]. 
Examples of IAPs include XIAP, cIAP-1, cIAP-2, Ts-IAP, NAIP, Survivin, Livin/
ML-IAP, and Apollon/Bruce. IAPs are characterised by the presence of BIR (bacu-
loviral IAP repeat) domain(s) required for suppression of apoptosis. Additionally, 
some members of the family may contain a RING finger domain at the C-terminus 
essential for ubiquitylation and subsequent proteasomal degradation of the apopto-
sis inducer proteins, caspases and Smac [155]. Indeed, it has been demonstrated that 
overexpression of IAPs suppress apoptosis [156]. Therefore, IAPs contribute to their 
anti-apoptosis function by promoting proteasomal degradation of pro-apoptotic 
caspases and Smac proteins. Targeting specific IAPs’ E3 ubiquitin ligase activity 
inhibition thus, has potential for anti-cancer drug development [140]. Additionally, 
research has shown overexpression of components of SCF of RING E3 ligases in 
several human cancers. For instance, Cul4A is reported to be overexpressed in 
breast cancers [157]. Skp2 is likewise overexpressed in other human cancers e.g., 
squamous, colorectal, gastric, and prostate carcinomas, small cell lung carcinoma, 
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and breast cancer. Skp1-Cullin-F Box components are the substrate recognition 
sites of the RING E3 ligases and recognise a variety of substrates involved in critical 
cellular processes such as the cell cycle. Examples of SCF targets for ubiquitin-
mediated proteasomal degradation are p27 and cyclin E which are down regulators 
of different sites of the cell cycle [44]. Furthermore, the role of Nedd4-1 in lung 
cancers has been studied (see 3.1 above). NEDD4-1 expression is up-regulated in 
lung adenocarcinoma compared with normal cells. It has also been demonstrated 
that NEDD4-1 silencing reduces non-small cell lung cancer cells in vitro as well as 
tumour growth in vivo [158]. Overexpression of Nedd4-1 is associated with lymph 
node metastasis and chemoresistance, as such NEDD4-1 is a potential drug target 
since specific inhibitors of NEDD4-1 will likely promote cancer cell apoptosis. 
NEDD4-1 E3 ligase activity inhibition therefore has potential for lung cancer treat-
ment [108].
Cbl E3 ligase (Section 3.1) ubiquitylates EGFR thereby reducing EGFR signal-
ling in glioblastoma. Specific inhibitors of Cbl could helpfully target upregulating 
EGFR signalling in anti-glioblastoma therapy. As the MAPK pathway is commonly 
mutated in many cancers resulting from increase in cellular proliferation, differ-
entiation, migration, and invasion, specific inhibitors of E3 ligases of the MAPK 
pathway (e.g., TRIM9, SCFFBXO31, KBTBD7, LZTR1) may have potential for 
anti-cancer therapy [72].
Research suggests that ubiquitylation of Plasmodium falciparum proteins 
play essential roles in parasite development. Recent data indicate ubiquitylation 
of several essential proteins (e.g., merozoite pellicle proteins involved in eryth-
rocyte invasion, exported proteins, and histones) of the human malaria parasite, 
Plasmodium falciparum, which suggest potential for the use of small-molecule 
inhibitors of the ubiquitin-mediated degradation machinery for the development 
of anti-malarial drugs [159]. The data further showed that some commercially 
available inhibitors of the ubiquitylation process e.g., the UBA1 inhibitor MLN7243, 
is a potent inhibitor and blocked schizont differentiation into merozoites by inter-
rupting nuclear division and intracellular structural formation. Identification of the 
associated E3 ligases will predictably present a varied number of druggable targets 
with potential for malaria treatment [159]. More research will unveil the most 
relevant E3s to target in this regard.
Finally, besides small-molecule E3 ligase inhibitors, PROTACs (PROteolysis-
TArgeting Chimeras) appear to have significant therapeutic potential. Reports 
indicate that small-molecule inhibitors have limitations [160]. For instance, small-
molecule inhibitors are limited to molecules that have an active site (enzymes and 
receptors e.g., RTKs). The PROTAC technology has emerged to overcome these 
limitations and to facilitate the 75% of human proteome e.g., transcription factors, 
scaffolding proteins, and non-enzymatic proteins which are signal effector proteins 
but lack active sites and are thus undruggable. The emerging characteristics of 
PROTACs such as induction of substrate selectivity, rapid, profound, and sustained 
proteasomal degradation and consequential induction of robust inhibition of 
downstream signals coupled with overcoming resistance to small molecule inhibi-
tors have been extensively reviewed [72, 160]. A PROTAC is a small heterobifunc-
tional molecule consisting of an E3 binding domain and a substrate binding domain 
covalently joined together by a linker. This spatial arrangement enhances recruit-
ment of the E3 enzyme in proximity with the specific substrate (e.g., an oncopro-
tein) for ubiquitylation and subsequent proteasomal degradation thereby inhibiting 
downstream signals and subsequently down regulating the cell cycle or inducing 
apoptosis. PROTAC technology therefore will utilise the E3-mediated ubiquitin 
proteasome mechanistic pathway to treat disease. It is a very promising alternative 
technique where E3 inhibitors are limited or will present less efficiency.
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4. Conclusion and perspectives
The biological importance of E3 ubiquitin ligases cannot be overemphasised 
because protein ubiquitylation is crucial in the regulation of numerous cellular 
processes. E3 ubiquitin ligases have therefore recently emerged as significant future 
therapeutic opportunities for drug development for treatment of several human 
diseases associated with ubiquitin-mediated signalling. Regrettably, the mecha-
nisms by which the ubiquitin system regulates cellular signalling and pathogenesis 
remain largely unknown. Many questions remain unanswered considering the 
number of E3 ligases (over 600) in the human genome and lack of the most relevant 
technologies to assess these principles, coupled with the extreme complexity of 
ubiquitin signalling processes. Blocking protein–protein interactions is problematic, 
yet it is apparently the most effective treatment option for utilising the ubiquitin 
system. This option relies on blocking the E3 ligase at specific substrate recogni-
tion sites. Hypothetically, targeting rapid screening of small specific molecular 
inhibitors of E3s which have potential to selectively stabilise specific downstream 
cellular proteins regulated by specific E3s while avoiding unwanted effects on other 
cellular proteins will achieve less toxicity. Therefore, a complete understanding 
of the mechanisms involved in protein substrate recognition by E3 ligases and 
functions, as well as easy identification of aberrant entities within the ubiquitin 
pathway will be instrumental in understanding the aetiology of associated diseases. 
With the current advances in proteomics technology, more E3 substrates are being 
identified and more insights to E3 regulatory roles in many diseases are being better 
understood. Though new technologies such as the siRNA, for validation of many 
E3s, the Fluorescence Resonance Energy Transfer (FRET) for High throughput 
(HTS) assays for screening inhibitors of ubiquitin transfer from E2s to E3s, and 
electrochemiluminescence (ECL)-Based HTS for screening inhibitors of the 
ubiquitylation machinery have facilitated screening of compounds against E3s and 
improved research in this aspect so far, these methods are themselves not devoid of 
challenges. Development of more efficient, cheaper, and simpler techniques will 
fast-track understanding of the ubiquitin system and the drug discovery process. 
Predictably, E3 ubiquitin ligases will present one of the most efficacious targets for 
anti-cancer drug discovery and for other diseases in the future.
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